Targeting pathways involved in oxidative stress and fibrosis, such as TXNIP, SNAI1, and related signaling pathways, can provide new therapeutic approaches in managing elevated IOP and mitigating glaucoma progression in diabetic patients. The gene discussed is TXNIP; the disease is glaucoma.